Ted is an accomplished executive and entrepreneur with more than 25 years of experience in therapeutics, diagnostics, and industrial synthetic biology. He co-founded Sestina and served as CTO, leading the development of new technologies combining ultra-high throughput measurement systems, high dimensional data generation and advanced computational tools. Prior to Sestina, he served in executive management/leadership roles at iCarbonX, HealthTell, Vanquish Oncology (Founder), Tethys Biosciences, Lawrence Livermore National Laboratory, Invenux Pharmaceuticals (Founder) and NeXstar Pharmaceuticals. Ted joined Inscripta as CTO in 2022 as part of the Sestina Bio acquisition.
Ted received his PhD in Organic Chemistry from The Scripps Research Institute and his BS degree in Chemistry from the California Polytechnic State University, San Luis Obispo (Summa Cum Laude).